| Identification | Back Directory | [Name]
Nemorubicin | [CAS]
108852-90-0 | [Synonyms]
MMRDX
DMM Dox
FCE 23762
PNU 152243
PNU-152243A
Nemorubicin
NeMorubincine
Nemorubicin (PNU 152243)
Methoxymorpholinyldoxorubicin
methoxy-morpholynil-doxorubicin
PNU152243A; PNU-152243A; PNU 152243A; NEMORUBICIN; METHOXYMORPHOLINYL-DOXORUBICIN
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-tetracenyl 2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 2,3,6-trideoxy-3-[(S)-2-methoxymorpholino]-alpha-L-lyxo-hexopyranoside
5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-2,3,6-trideoxy-3-(2S)-2-methoxy-4-morpholinyl-.alpha.-L-lyxo-hexopyranosyloxy-, (8S,10S)-
5,12-Naphthacenedione,7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-a-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-
5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- | [Molecular Formula]
C32H37NO13 | [MDL Number]
MFCD00871079 | [MOL File]
108852-90-0.mol | [Molecular Weight]
643.64 |
| Chemical Properties | Back Directory | [Boiling point ]
852.2±65.0 °C(Predicted) | [density ]
1.55±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:60.0(Max Conc. mg/mL);101.0(Max Conc. mM) | [form ]
Powder | [pka]
7.35±0.60(Predicted) | [color ]
Orange to reddish brown | [InChIKey]
CTMCWCONSULRHO-UZGLGGDGNA-N | [SMILES]
C12C[C@@](C[C@]([H])(O[C@@H]3O[C@H]([C@@H](O)[C@@H](N4CCO[C@H](OC)C4)C3)C)C=1C(O)=C1C(=O)C3=C(OC)C=CC=C3C(=O)C1=C2O)(O)C(=O)CO |&1:2,4,7,9,10,12,17,r| |
| Hazard Information | Back Directory | [Uses]
Nemorubicin is a doxorubicin derivative that differs significantly from its parent drug in terms of spectrum of antitumor activity, metabolism and toxicity profile. The drug is active on tumors resistant to alkylating agents, topoisomerase II inhibitors and platinum derivatives. It works primarily through topoisomerase I inhibition. Of note, Nemorubicin is active in cells with upregulation of the nucleotide excision repair (NER) pathway, where current therapies fail. Nemorubicin is biotransformed in the liver into cytotoxic metabolites that may further contribute to render this drug highly active against primary liver tumors or liver metastases. | [Definition]
ChEBI: Nemorubicin is a member of morpholines, an anthracycline antibiotic, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. It is functionally related to a doxorubicin. | [in vivo]
Nemorubicin is converted to PNU-159682 by human liver cytochrome P450 (CYP) 3A4 in rat, mouse, and dog liver microsomes[2].
Nemorubicin (60 μg/kg) induces sifnificant tumor growth delay in scid mice bearing 9L/3A4 tumors, but shows no obvious effect on the tumor growth delay of 9L tumors in mice by i.v. or intratumoral injection (i.t.). Nemorubicin (40 μg/kg, i.p.) exhibits no antitumor activity and no host toxicity in mice bearing 9L/3A4 tumors[4]. | [target]
cancer | [storage]
Store at -20°C |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|